The brain's cleaning system can be boosted to rid Alzheimer's proteins
Why it matters: This discovery could delay Alzheimer's onset by years, offering hope for millions.
- ACX-02, a combination of dexmedetomidine and midodrine, was found to effectively clear amyloid and tau proteins associated with Alzheimer's in human trials.
- Shiju Gu at Harvard University highlights this as a significant advancement, suggesting potential benefits for both neurodegenerative disease patients and healthy individuals seeking to maximize brain function.
- Paul Dagum and his team at Applied Cognition conducted human trials with 19 adults, demonstrating ACX-02's ability to enhance the glymphatic system's waste-clearing function, particularly during sleep.
- The glymphatic system, responsible for removing metabolic waste, is most active during deep sleep but becomes impaired with age and Alzheimer's, making its enhancement a key therapeutic target.
A groundbreaking drug combination, ACX-02, has been identified that significantly boosts the brain's natural waste-disposal system, effectively clearing proteins linked to Alzheimer's disease. This therapy, combining a sedative with a blood pressure regulator, shows promise in delaying the disease's onset by an estimated seven years, offering a new avenue for treatment and prevention.
